Feb. 26, 2025 — iCAD, Inc. a provider of clinically proven AI-powered cancer detection solutions, and Koios Medical, a leader in AI-driven ultrasound cancer diagnosis, have entered a strategic reseller partnership to deliver a comprehensive, multi-modality AI suite for breast cancer detection. This collaboration integrates iCAD’s ProFound AI Breast Health Suite for mammography with Koios SmartUltrasound, providing radiologists with an AI-powered pathway from screening to diagnosis.
“iCAD has long been a leader, the pioneer in AI for breast imaging. It is an honor to collaborate with a company with an unmatched track record of improving clinical outcomes for patients and a rich history of innovation,” said Chad McClennan, president and CEO of Koios Medical, Inc.
The partnership reflects the rapidly growing adoption of AI solutions across breast imaging facilities. “Our collaboration with iCAD is ultimately a customer-driven initiative. Breast imaging radiologists have long embraced innovation and are rapidly adopting best-of-breed AI solutions. Physicians seek accuracy, efficiency, and peace of mind. By offering an integrated ‘breast AI suite’ that includes both iCAD’s ProFound AI and Koios SmartUltrasound, we’re enabling a more comprehensive, AI-enhanced patient pathway. Streamlining AI acquisition and implementation across both mammography and breast ultrasound is a logical and necessary step forward,” said Chad McClennan, President & CEO of Koios Medical, Inc.
Dana Brown, president and CEO of iCAD, added, “This partnership reinforces iCAD’s commitment to delivering innovative AI solutions that empower radiologists and improve patient outcomes. By integrating iCAD’s ProFound AI Breast Health Suite with Koios SmartUltrasound, we are providing clinicians with a more complete, end-to-end, AI-powered approach to breast cancer screening and detection that enhances workflow efficiency and diagnostic accuracy.”
Koios SmartUltrasound is an AI-based software platform proven to accurately detect and diagnose both thyroid and breast cancers in ultrasound exams. Built using data sourced from a global network of partner sites, the technology aids physicians in quickly and accurately diagnosing disease, improving speed of interpretation, automating reporting, and reducing time to treatment, all while avoiding unnecessary surgical procedures. The increasing utilization of ultrasound in cancer detection, particularly for women with dense breast tissue, makes this innovation particularly relevant in today’s evolving healthcare landscape.
For more information, please visit www.icadmed.com.
July 17, 2024 
